5 Key Takeaways

• 1

  The FDA has approved Boston Scientific’s Farapulse system for treating refractory, recurrent, symptomatic paroxysmal atrial fibrillation.

• 2

  Farapulse is the second FDA-approved pulsed-field ablation system for this patient population, following Medtronic’s PulseSelect.

• 3

  In the ADVENT trial, Farapulse was noninferior to thermal ablation in safety and efficacy after one year.

• 4

  Farapulse showed shorter procedural duration but longer fluoroscopy duration compared to thermal ablation.

• 5

  Real-world data indicated low major complication rates with Farapulse, with no cases of phrenic nerve palsy or esophageal injury.